15-min delayed · Jul 27, 3:45 PM ET · Get real-time quotes →
The Quantellect read.Of the 2 firms covering Verrica Pharmaceuticals Inc, 2 rate it Buy or better, 0 sit at Hold, and 0 rate it Sell or worse, a moderate buy consensus. Targets span $12.00 to $17.00, a moderate spread. The average target of $14.50 sits 174% above the current $5.29. The rating mix has stayed broadly stable, with Buy-side ratings edging up from 1 to 2 over recent months. On the fundamentals, the Street sees consensus EPS building from about $-0.43 next quarter toward $-1.24 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS2 ratings
Moderate Buy
Strong Buy00%
Buy2100%
Hold00%
Sell00%
Strong Sell00%
Based on 2 analysts giving stock ratings to Verrica Pharmaceuticals Inc.
As of Jul, 2 of 2 firms rate VRCA a Buy (0 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
VRCA EPS & revenue forecast
EPS · NEXT QUARTER
$-0.43
Range $-0.47 – $-0.39 · 3 analysts · -428% YoY
Next period, 3 analysts expect Verrica Pharmaceuticals Inc to earn $-0.43 a share (range $-0.47 – $-0.39), versus $0.13 a year earlier. Full-year consensus is $-1.73, growing to $-1.24 the year after.
REVENUE · NEXT QUARTER
$6.8M
Range $5.0M – $8.6M · 3 analysts · -52% YoY
Revenue is expected to reach $6.8M (range $5.0M – $8.6M), -52.3% year-over-year. Full-year consensus is $25.5M, rising to $46.3M next year.
Top analysts covering Verrica Pharmaceuticals Inc
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on VRCA.
#1
Serge Belanger
Needham · Rank #83
Hold
No targeton VRCA
Overall win rate
48%
+ Follow
#2
Oren Livnat
HC Wainwright & Co. · Rank #142
Hold
No targeton VRCA
Overall win rate
54%
+ Follow
#3
Gregory Renza
RBC Capital · Rank #179
Hold
$2.00-62.2% to target
Overall win rate
34%
+ Follow
#4
Raghuram Selvaraju
HC Wainwright & Co. · Rank #249
Buy
$12.00+126.8% to target
Overall win rate
37%
+ Follow
#5
KD
Kemp Dolliver
Brookline Capital
Buy
$17.00+221.4% to target
Coverage
—
+ Follow
VRCA stock forecast FAQ
What is VRCA's average 12-month price target?+
The 2 analysts with a live target average $14.50 for Verrica Pharmaceuticals Inc over the next 12 months, ranging from a $17.00 high to a $12.00 low.
Is VRCA stock a Buy, Sell or Hold right now?+
The current consensus is Moderate Buy. Of the 2 analyst ratings, 2 are Buy or Strong Buy, 0 are Hold, and 0 are Sell or Strong Sell.
What are the highest and lowest price targets for VRCA?+
The Street-high target is $17.00 (Brookline Capital), and the Street-low is $12.00 (HC Wainwright & Co.). The average of all 2 active targets is $14.50.
How many Wall Street analysts cover VRCA?+
2 analysts have an active rating on Verrica Pharmaceuticals Inc, and 2 firms carry a live 12-month price target.
Who is the most accurate analyst covering VRCA?+
Among analysts who currently cover VRCA, Serge Belanger of Needham has the strongest overall Quantellect track record (Rank #83). Their current call is Hold.
What is Verrica Pharmaceuticals Inc's projected EPS for next quarter?+
The consensus estimate is $-0.43 per share (range $-0.47 – $-0.39) across 3 analysts. Full-year EPS is projected at $-1.73, rising to $-1.24 the following year.
How much revenue is Verrica Pharmaceuticals Inc expected to report next quarter?+
Consensus revenue is $6.8M (range $5.0M – $8.6M). Full-year revenue is projected at $25.5M, growing to $46.3M next year.
Have analysts been upgrading or downgrading VRCA lately?+
As of Jul, 2 of 2 firms rate VRCA a Buy (0 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their VRCA calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.
